Julien Mazieres, Coordinator of the Transversal Federation of Oncology at CHU of Toulouse, shared on X:
“Another brick in the wall of HER2 mut NSCLC. Promising efficacy of BAY in HER2 naive pts (ORR 70.5%) but also in pts treated with TDxD (ORR 35.3%). Diarrhea as the most frequent AE (almost all pts but no tt discontinuation).”
